Accessibility Menu
Merus logo

Merus(NASDAQ) MRUS

This security has been delisted. This page is retained for historical reference.

Merus last closing stock price
MetricPriceDate
Last closeUSD 90.002025-12-29
Merus stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.17%USD 96.952025-12-22
1 month-6.39%USD 96.142025-11-28
3 month-4.41%USD 94.152025-09-30
Year to date+114.03%USD 42.052024-12-31
1 year+113.93%USD 42.072024-12-27
3 year+481.77%USD 15.472022-12-30
5 year+411.07%USD 17.612020-12-30
Since inception+796.41%USD 10.042016-05-19

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

MRUS Financials

Key Financial Metrics (TTM)

Gross Margin

-249.98%

Operating Margin

-589.59%

Net Income Margin

-722.94%

Return on Equity

-45.59%

Return on Capital

-39.92%

Return on Assets

-41.32%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$109.62M

Operating Income

-$345.75M

EBITDA

-$323.66M

Operating Cash Flow

-$317.27M

Capital Expenditure

-$607.00K

Free Cash Flow

-$317.87M

Cash & ST Invst.

$542.95M

Total Debt

$10.52M

Merus Performance Analysis

Merus annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 49,107,000N/A
20222022-12-31USD 41,586,000-15.3%
20232023-12-31USD 43,947,0005.7%
20242024-12-31USD 36,133,000-17.8%
Merus sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-16.5%
Q12025-03-31177.5%
Q22025-06-30-69.4%
Q32025-09-3062.1%
Merus annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -1.73N/A
20222022-12-31USD -2.9268.9%
20232023-12-31USD -3.002.8%
20242024-12-31USD -3.3511.7%
Merus sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-3169.2%
Q12025-03-31-211.1%
Q22025-06-30-59.3%
Q32025-09-3043.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$12.15M

+14.9%

Gross Profit

$11.51M

+178.2%

Gross Margin

94.71%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

260

N/A

Net Income

-$95.52M

-6.5%

EBITDA

-$76.04M

-18.3%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

$542.95M

-14.1%

Total Debt

$10.52M

-4.8%

Accounts Receivable

$19.41M

+399.9%

Inventory

$0.00

N/A

Long Term Debt

$8.16M

-12.1%

Short Term Debt

$2.36M

+33.8%

Return on Assets

-41.32%

N/A

Return on Invested Capital

-37.28%

N/A

Free Cash Flow

-$85.25M

-5.6%

Operating Cash Flow

-$84.92M

-5.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CYTKCytokinetics, Incorporated
$81.91+0.99%
NUVLNuvalent, Inc.
$123.96+0.00%
ABVXAbivax S.A.
$131.20-2.16%
AXSMAxsome Therapeutics, Inc.
$236.03-0.39%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.64+0.01%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$35.12-0.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.84-0.01%
SMCXTidal Trust II - Defiance Daily Target 2x Long Smci ETF
$9.21+0.43%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.